Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07686302

Feasibility of Noninvasive Trigeminal Nerve Stimulation During Exercise

The purpose of this study is to examine 1) effects of cutaneous electrical trigeminal nerve stimulation (eTNS) on respiratory control in healthy volunteers and 2) explore the potential of this approach to mitigate dyspnea in patients with chronic obstructive lung disease (COPD).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Arm1 - Healthy Volunteers

Inclusion criteria

  • Adults aged 18-50 years
  • BMI 18-30 kg/m²
  • Ability to provide informed consent and complete study procedures in English

Exclusion criteria

  • Current daytime respiratory impairment such as uncontrolled asthma, uncontrolled COPD, pneumonia, or interstitial lung disease
  • Use of supplemental oxygen
  • Pregnancy or breastfeeding
  • Current use of acetazolamide, Sodium-glucose cotransporter-2 (SGLT2) inhibitors, or daily opioids
  • History of claustrophobia or panic disorder
  • Metallic implants in the craniofacial or cervical region that may interfere with electrode placement or electrical stimulation
  • Implanted cardiac or neuroelectric device (e.g., pacemaker, implantable cardioverter-defibrillator (ICD), deep brain stimulator, vagus nerve stimulator, implanted drug pump)
  • Open, broken, inflamed, infected, or healing skin lesions at or near facial electrode placement sites
  • Resting heart rate <60 Beats Per Minute
  • History of seizure disorder or epilepsy

Arm 2 -COPD

Inclusion criteria

  • Adults aged 40-75 years
  • Confirmed diagnosis of COPD by spirometry (post-bronchodilator Forced Expiratory Volume (FEV1) /Forced Vital Capacity (FVC) <0.70) or provider documentation in medical records
  • Modified Medical Research Council (mMRC) dyspnea grade ≥2
  • Stable COPD (no exacerbation requiring hospitalization, systemic corticosteroids, or antibiotic therapy within the preceding 6 weeks)
  • On stable COPD therapy for at least 4 weeks prior to enrollment
  • Ability to provide informed consent and complete questionnaires in English
  • Resting Peripheral Capillary Oxygen Saturation (SpO₂) ≥88% on room air or prescribed supplemental oxygen

Exclusion criteria

  • Unstable cardiovascular disease (e.g., unstable angina, decompensated heart failure, recent MI within 6 months, uncontrolled arrhythmia) or peripheral vascular disease
  • Patients with cardiovascular disease, including chest pain, heart failure, and aortic stenosis
  • Resting heart rate <60 BPM
  • Implanted cardiac or neuroelectric device (e.g., pacemaker, ICD, deep brain stimulator, vagus nerve stimulator, implanted drug pump)
  • Metallic implants in the craniofacial or cervical region that may interfere with electrode placement or stimulation
  • Open, broken, inflamed, infected, or healing skin lesions at or near facial electrode placement sites
  • Active trigeminal neuralgia or other cranial neuropathy
  • History of seizure disorder or epilepsy
  • Severe or uncontrolled psychiatric disorder (e.g., psychosis, severe untreated anxiety or panic disorder) that would impair the ability to participate
  • Pregnancy or breastfeeding
  • COPD exacerbation requiring hospitalization, systemic corticosteroids, or antibiotics within the preceding 3 months
  • Musculoskeletal pain, injury, or any other condition that precludes the use of a stationary bike for Cardiopulmonary Exercise Test (CPET)
  • Any condition that, in the opinion of the investigator, would compromise participant safety or data integrity

Treatment and study plan

active stimulation

Procedure

Active Non-Invasive Trigeminal Nerve Stimulation

Sham stimulation

Procedure

Sham Stimulation

Fan therapy

Procedure

Handheld fan

Primary outcomes

  1. Proportion of participants with a >4 bpm decrease in heart rate

    Time frame: 1 day

    Trigeminal autonomic engagement. Proportion of participants with a >4 bpm decrease in heart rate during active eTNS compared to sham stimulation.

  2. Proportion of enrolled participants who complete all randomized stimulation conditions

    Time frame: 1 day

    Protocol completion rate measured by proportion of enrolled participants who complete all randomized stimulation conditions.

Secondary outcomes

  1. Minute Ventilation

    Time frame: 1 day

    Minute Ventilation

  2. Dyspnea severity as assessed by the Borg CR10 scale

    Time frame: 1 day

    Borg CR10 score before and during stimulation. Scale range 0-10 higher score worse severity

Other outcomes

  1. Change in heart rate

    Time frame: 1 day

    changes in heart rate in response to stimulation

  2. Change in heart rate variability

    Time frame: 1 day

    changes in heart rate variability in response to stimulation

Study contacts

Contact information is provided by the study sponsor or research team.

Luu Pham, MD

CONTACT

[email protected]

410-550-2118

Sponsors and collaborators

Lead sponsor

Johns Hopkins University

Other

Collaborators

  • Center for Bioengineering Innovation and Design

Registry information

Official study title

Noninvasive Trigeminal Nerve Stimulation for Dyspnea: Mechanistic Characterization in Healthy Volunteers and Feasibility in COPD

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jul 7, 2026
Registry last updated
Jul 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.